CA2337772C - Skin and tissue care and/or treatment agent - Google Patents
Skin and tissue care and/or treatment agent Download PDFInfo
- Publication number
- CA2337772C CA2337772C CA002337772A CA2337772A CA2337772C CA 2337772 C CA2337772 C CA 2337772C CA 002337772 A CA002337772 A CA 002337772A CA 2337772 A CA2337772 A CA 2337772A CA 2337772 C CA2337772 C CA 2337772C
- Authority
- CA
- Canada
- Prior art keywords
- preparation
- peroxide
- metal salts
- skin
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 claims abstract description 93
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 36
- 150000001413 amino acids Chemical class 0.000 claims abstract description 32
- 239000000126 substance Substances 0.000 claims abstract description 25
- -1 alkaline earth metal salts Chemical class 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 18
- 239000011787 zinc oxide Substances 0.000 claims abstract description 18
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 17
- 235000010755 mineral Nutrition 0.000 claims abstract description 17
- 239000011707 mineral Substances 0.000 claims abstract description 17
- 150000002978 peroxides Chemical class 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 16
- 235000013343 vitamin Nutrition 0.000 claims abstract description 16
- 239000011782 vitamin Substances 0.000 claims abstract description 16
- 229940088594 vitamin Drugs 0.000 claims abstract description 16
- 229930003231 vitamin Natural products 0.000 claims abstract description 16
- 239000011573 trace mineral Substances 0.000 claims abstract description 11
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 11
- 239000002502 liposome Substances 0.000 claims abstract description 10
- 239000000341 volatile oil Substances 0.000 claims abstract description 10
- 229960003237 betaine Drugs 0.000 claims abstract description 9
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 9
- 239000003906 humectant Substances 0.000 claims abstract description 8
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011230 binding agent Substances 0.000 claims abstract description 7
- 229960004995 magnesium peroxide Drugs 0.000 claims abstract description 7
- 239000000853 adhesive Substances 0.000 claims abstract description 6
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 6
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 6
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 6
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 229940024606 amino acid Drugs 0.000 claims description 31
- 235000001014 amino acid Nutrition 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229960003121 arginine Drugs 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 229930003935 flavonoid Natural products 0.000 claims description 7
- 235000017173 flavonoids Nutrition 0.000 claims description 7
- 150000002215 flavonoids Chemical class 0.000 claims description 7
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 235000013311 vegetables Nutrition 0.000 claims description 7
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical group [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 claims description 6
- 229940105296 zinc peroxide Drugs 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 201000009053 Neurodermatitis Diseases 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 229960002743 glutamine Drugs 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 206010007882 Cellulitis Diseases 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 206010018852 Haematoma Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 206010040880 Skin irritation Diseases 0.000 claims description 3
- 206010040954 Skin wrinkling Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000003518 caustics Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229960002433 cysteine Drugs 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003075 phytoestrogen Substances 0.000 claims description 3
- 229940068065 phytosterols Drugs 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 235000017709 saponins Nutrition 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 230000036556 skin irritation Effects 0.000 claims description 3
- 231100000475 skin irritation Toxicity 0.000 claims description 3
- 150000004763 sulfides Chemical class 0.000 claims description 3
- 150000003505 terpenes Chemical class 0.000 claims description 3
- 235000007586 terpenes Nutrition 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004343 Calcium peroxide Substances 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019402 calcium peroxide Nutrition 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 208000014617 hemorrhoid Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000003513 alkali Substances 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 230000004060 metabolic process Effects 0.000 description 12
- 230000004089 microcirculation Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 241000208690 Hamamelis Species 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- 235000009569 green tea Nutrition 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 150000003862 amino acid derivatives Chemical class 0.000 description 5
- 229940093797 bioflavonoids Drugs 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000002066 eicosanoids Chemical class 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000011133 lead Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000003880 Calendula Nutrition 0.000 description 2
- 240000001432 Calendula officinalis Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 240000008669 Hedera helix Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 244000141009 Hypericum perforatum Species 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 230000037204 skin physiology Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 235000004758 Bergkiefer Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241001264766 Callistemon Species 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000331124 Krameria argentea Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000010450 Pino mugo Nutrition 0.000 description 1
- 241001136577 Pinus mugo Species 0.000 description 1
- 235000002914 Pinus uncinata Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000016911 Ribes sativum Nutrition 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 244000281209 Ribes triste Species 0.000 description 1
- 235000016897 Ribes triste Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- SSBRSHIQIANGKS-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;hydrogen sulfate Chemical class NC(N)=O.OS(O)(=O)=O SSBRSHIQIANGKS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000002201 avitaminosis Nutrition 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 244000059217 heterotrophic organism Species 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960001682 n-acetyltyrosine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000003259 prostaglandin group Chemical group 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a skin and tissue care and/or treatment preparation.
In particular, the invention relates to a preparation for care, protection and prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue, wherein said preparation comprises at least one salt selected from alkali and alkaline earth metal salts and other minerals and is characterized in that it contains at least one amino acid and zinc oxide and/or an inorganic peroxide, preferably magnesium peroxide or sodium peroxide. Optionally, the inventive preparation can additionally contain an adstringent, a binding and adhesive agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and/or antimicrobial components.
In particular, the invention relates to a preparation for care, protection and prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue, wherein said preparation comprises at least one salt selected from alkali and alkaline earth metal salts and other minerals and is characterized in that it contains at least one amino acid and zinc oxide and/or an inorganic peroxide, preferably magnesium peroxide or sodium peroxide. Optionally, the inventive preparation can additionally contain an adstringent, a binding and adhesive agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and/or antimicrobial components.
Description
SKIN AND TISSUE CARE AND/OR TREATMENT AGENT
The invention relates to a skin and tissue care and/or treatment preparation.
In particular, the invention relates to a preparation for care, protection and prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue, wherein said preparation comprises at least one salt selected from alkali and aikaline earth metal salts and other minerals and is characterized in that it contains at least one amino acid and zinc oxide and/or an inorganic peroxide, preferably magnesium peroxide or sodium peroxide. Optionally, the inventive preparation can additionally contain an adstringent, a binding and adhesive agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and/or antimicrobial components.
Natural nutrients are essential for the health of cells and body. They serve to maintain and regenerate the skin as well as to stimulate metabolism and oxygen supply of the cells. The extensive significance of nutrient supply becomes also more and more important in the field of skin care, cosmetic and dermatology.
Hormonal modifications, predisposition, an unbalanced and wrong diet and unhealthy. habits, especially smoking and lack of exercise, lead to typical manifestations of the skin, such as tissue modifications, tissue deformations and cellular metabolic disturbances. A well-aimed supply of nutrients harmonizes metabolism and thus results in a natural, physiological equilibrium of the cells.
It is generally known that vitamins, minerals and trace elements are indispensable to the nutrient supply of the skin. Proteins which are built up of amino acids are an important building component for cells and endogenous active substances, such as enzymes and certain hormones. Polyunsaturated fatty acids, secondary plant substances, such as flavonoids and epigallocatechines, and liposomes in general are becoming more and more important for health and fitness. Vitamins, minerals and trace elements, polyunsaturated fatty acids and bioactive plant substances such as flavonoids are essential regulators in the metabolism and protective nutrients for the health of the skin.
Vitamins are essential nutritional components which, for the normal functions of heterotrophic organisms, have to be supplied more or less obligatorily and in correspondence to the needs, since they are only available either from external sources or under the influence of millieu factors (e.g. intestinal flora).
Their specific biocatalytic effect is based on the replacement of the active groups of enzymes which are subject to metabolical consumption. From science it is for example known that B-type vitamins contribute to the intermediary metabolism as coenzymes and that vitamins C, E and R-carotene mainly function as antioxidants.
Deficiencies resulting from insufficient supply or resorption, disorders of the intestinal flora or of metabolism, antivitamin-effect or increased consumption lead to hypovitaminosis and avitaminosis.
Furthermore, minerals and trace elements are essential regulators in the metabolism. Zinc, magnesium and the B-type vitamins are high-performance elements - as they activate enzymes and thus allow the metabolism of carbohydrates, fats and protein substances. Silicon has a favorable effect on stability and maintenance of the skin. Furthermore, it is scientifically undisputed that zinc has an essential function in the immune system and in the metabolism of the skin.
Polyunsaturated fatty acids contain linolic acid, and a- and y-linolenic acid, which are important starting substances for biologically active regulators in the metabolism, such as eicosanoids and prostaglandins, and which ensure a healthy equilibrium in the metabolism. Currently, eicosanoids and prostagiandins, also referred to as tissue hormones, are being intensively examined by scientists with regard to their health stabilizing effect. The favorable influence of the polyunsaturated fatty acids on the healthy skin function as well as on inflammatory processes is known. Furthermore, it is known that polyunsaturated fatty acids of the type of the w-3-(eicosapentaenoicacid, a-Iinolenic acid) and co-6-fatty acids (linolic acid, y-linolenic acid) have favorable effects on neurodermatitis and psoriasis as well as regeneration processes induced by physical strain during exercise. The importance of the so-called secondary plant substances, in the special branch of science also referred to as bioactive plant substances, for health is now being examined as well. Bioflavonoids, which effectively support the effects of vitamin C with regard to the power of resistance, vascular walls and connective tissue also count among these natural plant substances. Furthermore, it is known that bioflavonoids have antioxidant properties and that they thus synergistically complement the effect of the vitamins C, E and (3-carotene.
The invention relates to a skin and tissue care and/or treatment preparation.
In particular, the invention relates to a preparation for care, protection and prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue, wherein said preparation comprises at least one salt selected from alkali and aikaline earth metal salts and other minerals and is characterized in that it contains at least one amino acid and zinc oxide and/or an inorganic peroxide, preferably magnesium peroxide or sodium peroxide. Optionally, the inventive preparation can additionally contain an adstringent, a binding and adhesive agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and/or antimicrobial components.
Natural nutrients are essential for the health of cells and body. They serve to maintain and regenerate the skin as well as to stimulate metabolism and oxygen supply of the cells. The extensive significance of nutrient supply becomes also more and more important in the field of skin care, cosmetic and dermatology.
Hormonal modifications, predisposition, an unbalanced and wrong diet and unhealthy. habits, especially smoking and lack of exercise, lead to typical manifestations of the skin, such as tissue modifications, tissue deformations and cellular metabolic disturbances. A well-aimed supply of nutrients harmonizes metabolism and thus results in a natural, physiological equilibrium of the cells.
It is generally known that vitamins, minerals and trace elements are indispensable to the nutrient supply of the skin. Proteins which are built up of amino acids are an important building component for cells and endogenous active substances, such as enzymes and certain hormones. Polyunsaturated fatty acids, secondary plant substances, such as flavonoids and epigallocatechines, and liposomes in general are becoming more and more important for health and fitness. Vitamins, minerals and trace elements, polyunsaturated fatty acids and bioactive plant substances such as flavonoids are essential regulators in the metabolism and protective nutrients for the health of the skin.
Vitamins are essential nutritional components which, for the normal functions of heterotrophic organisms, have to be supplied more or less obligatorily and in correspondence to the needs, since they are only available either from external sources or under the influence of millieu factors (e.g. intestinal flora).
Their specific biocatalytic effect is based on the replacement of the active groups of enzymes which are subject to metabolical consumption. From science it is for example known that B-type vitamins contribute to the intermediary metabolism as coenzymes and that vitamins C, E and R-carotene mainly function as antioxidants.
Deficiencies resulting from insufficient supply or resorption, disorders of the intestinal flora or of metabolism, antivitamin-effect or increased consumption lead to hypovitaminosis and avitaminosis.
Furthermore, minerals and trace elements are essential regulators in the metabolism. Zinc, magnesium and the B-type vitamins are high-performance elements - as they activate enzymes and thus allow the metabolism of carbohydrates, fats and protein substances. Silicon has a favorable effect on stability and maintenance of the skin. Furthermore, it is scientifically undisputed that zinc has an essential function in the immune system and in the metabolism of the skin.
Polyunsaturated fatty acids contain linolic acid, and a- and y-linolenic acid, which are important starting substances for biologically active regulators in the metabolism, such as eicosanoids and prostaglandins, and which ensure a healthy equilibrium in the metabolism. Currently, eicosanoids and prostagiandins, also referred to as tissue hormones, are being intensively examined by scientists with regard to their health stabilizing effect. The favorable influence of the polyunsaturated fatty acids on the healthy skin function as well as on inflammatory processes is known. Furthermore, it is known that polyunsaturated fatty acids of the type of the w-3-(eicosapentaenoicacid, a-Iinolenic acid) and co-6-fatty acids (linolic acid, y-linolenic acid) have favorable effects on neurodermatitis and psoriasis as well as regeneration processes induced by physical strain during exercise. The importance of the so-called secondary plant substances, in the special branch of science also referred to as bioactive plant substances, for health is now being examined as well. Bioflavonoids, which effectively support the effects of vitamin C with regard to the power of resistance, vascular walls and connective tissue also count among these natural plant substances. Furthermore, it is known that bioflavonoids have antioxidant properties and that they thus synergistically complement the effect of the vitamins C, E and (3-carotene.
With regard to biosynthesis aspects, amino acids are divided into essential, semi-essential and non-essential amino acids. In addition to their function as building blocks for proteins, amino acids are precursors of biologically effective compounds. Amino acids are i.a. described in L. Stryer, Biochemie, Spektrum Akademischer Verlag, Oxford, 1994 and in Rompp Lexikon Chemie, editor J.
Falbe and M. Regitz, keyword "amino acids", Thieme Verlag, 1996 and bibliographic references cited therein.
Liposomes are particles surrounded by single or multi-layered phospholipid double membranes which can be loaded with hydrophilic pharmaceutical molecules in the inner, aqueous phase. By using them as pharmaceutical carriers, a selective local enrichment of active substances and a delayed release of active substances can be achieved.
Numerous preparations for treating and preventing mycotic, microbic, pathologic and other tissue-damaging manifestations and effects, tissue modifications, tissue deformations and cellular metabolic disturbance and other forms of damage to human tissue are commercially available. There are, for example, various therapeutic approaches for treating skin and connective tissue problems. The success of many of these preparations is, however, questionable, as these preparations are unable to reach the damaged cells and/or to act in the damaged cells. Furthermore, many of the products that are commercially available do not take the active mechanism discovered by scientists into account in which the cell is remineralized in a natural way and metabolism is stimulated so that the natural inner pressure of the cell is reestablished, the cell volume is normalized and fat and slag substances are effectively displaced and secreted.
DE-OS-196 22 708 describes a phytobiological preparation for the topical and parenteral incorporal application for preventing, caring for and treating various pathological and other endogenic and exogenic effects, modifications and diseases, as well as for maintaining, healing and reestablishing the homeostasis in and at animal and human organs and soft tissue, characterized in that it contains the following components:
(a) one or more ion-containing components and mineral salts, (b) one or more adstringent components, one or more binding agents, a humectant and one or more ethereal oils, and (c) optionally one or more vegetable extracts, a gelling agent, acid bondings, hyaluronidase or other suitable components in an amount between 0.01 and 20%. This preparation can optionally contain calendula, hamamelis or other homeopathic components, amino acids, enzymes, vitamins, electrolytes, dyes, wax, emulgators, starch, vaseline, paraffines, oils, acids, fats, vegetable mixtures and extracts, urea, sulfate compounds, etc. Neither does the patent application disclose examples of amino acids nor are amino acids used in the examples.
An object'of the present invention is to provide a skin and tissue care and/or treatment preparation which distinguishes itself by a quick effect, excellent tolerance, a broad field of application and particularly intense deep action.
In particular, the preparation is supposed to be applicable for care, protection, prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue. The preparation according to the invention is supposed to take into account research results concerning the diffusion of ions through ion channels into the intracellular space and improve microcirculation in the cell.
An object of the present invention is solved by the provision of a composition comprising the following components:
(a) at least one salt selected from alkali and alkaline earth metal salts and other minerals, characterized in that it contains (b) at Ieast one amino acid, and (c) zinc oxide and/or an inorganic peroxide.
Preferably zinc oxide, magnesium peroxide or sodium peroxide are used as component (c) of the composition.
In preferred embodiments the inventive preparation can additionally comprise, each independent of the other, at least one adstringent agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as flavonoids and epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and antimicrobial components. Furthermore, it can comprise usual carriers and adjuvants as well as binding and adhesive agents and usual solvents.
In a preferred embodiment the preparation of the present invention is topically used through direct application at the site of action.
The preparation of the present invention takes into account new research results concerning the diffusion of ions through ion channels into the intracellular space.
Hereby ions of mineral salts penetrate through the upper skin layers deep into the cell interior of hypoderm, connective tissue and fat cells. The inventive preparation uses i.a. the principle of ion exchange between cell interior and cell exterior using high osmotic pressure which is created by the combination of active substances of the preparation. In this process, however, the amino acids, which help the ions to more effectively overcome the natural barriers of the cell membranes to reach the cell interior, which is the actual site of action, play an important role.
The inventive composition is in particular still effective if the functional capability of the cell regarding ion activity is limited. Particularly when the ion activity is limited, the amino acids act as additional carriers for substances which must be infiltrated for the intracellular activity in order to be functionally effective therein.
It has been found that the combination of amino acids and zinc oxide and/or inorganic peroxides improves the microcirculation in the cell, compared to the use of salts.
The improvement can visually and biometrically be shown. If only salts are used, an increase of the microcirculation in the cell abruptly falls back to the starting value after about 1.5 hours. When the inventive composition comprising the combination of amino acids and zinc oxide and/or inorganic peroxides is used, the improvement of microcirculation is, compared to the use of salt, greater, more steady, lasts longer and approaches the starting value slowly. This allows a better infiltration of agents into and a better distribution of agents in the cell, which increases the synergistic effect.
Furthermore, in contrast to the salts alone, a combination of salts and amino acids has a greater positive effect on the skin physiology. This affects in particular the moisturing, factor, the pH value and the sebometry of the skin. When salts are used in combination with amino acids, the salts are infiltrated into the cell more effectively than without amino acids, as amino acids are, on the one hand, a key for the cell membranes and, on the other hand, support and increase the activation of the ion channels.
Alkali and alkaline earth metal salts and other minerals are essential regulators in the metabolism. In the present invention all known alkali and alkaline earth metal salts and minerals, which can also be present as trace elements, can be used.
Preferred representatives of the group of alkali and alkaline earth metal salts and minerals that can be used in the present invention are sodium, potassium, magnesium, calcium, silicon, zinc, manganese, copper, iron, fluorine, chlorine, bromine, iodine and phosphorus. Preferred trace elements are accidental trace elements, such as silver, gold, aluminum, barium, bismuth, cadmium, chrome, nickel, lead, tin, titanium and vanadium, and essential trace elements, such as chrome, cobalt, copper, fluorine, iron, iodine, manganese, molybdenum and selenium, which are present in, for example, enzymes, chromoproteines and hormones as constituents. The amount of the alkali and alkaline earth metal salts and other minerals in the inventive preparation is preferably 10 to 90 percent by weight, more preferably 20 to 85 percent by weight, particularly in topically applicable agents 10 to 30 percent by weight, more preferably 10 to 25 percent by weight, based on the sum of all components in the preparation, depending on the desired osmotic effect. The alkali and alkaline earth metal salts and the other minerals are added in the form of usual salt compounds or organic compounds.
For example, sodium, potassium and magnesium are preferably added in the form of their chloride salts, sodium and calcium in the form of phosphates.
The adstringent agents which are optionally used in the present invention comprise usual compounds for this purpose. Tannin, hamamelis, rhubarb, rhatany, and salvia are preferably used as adstringent. The amount of the adstringent agents in the inventive preparation is preferably 0 to 30 percent by weight, more preferably 1 to 25 percent by weight, based on the sum of all components in the preparation. The adstringent agents are preferably added in a pure form.
In the present invention usual humectants can optionally be used. Preferred humectants are glycerin, aloe vera, collagen, desamidocollagen, collagen hydrolysates, elastin hydrolysates, hyalomucco solution, fibrostimulin, PN 73, Q 10, water, aloe barbadensis gel, camelia sinensis extract, hedera helix, matricaria (camomile recutita) oil and butylene glykol. The amount of the humectants in the inventive preparation is preferably 0 to 70 percent by weight, more preferably 5 to 50 percent by weight, based on the sum of all components in the preparation.
Furthermore, the preparation of the present invention can optionally comprise usual ethereal oils. Preferred ethereal oils are oils of camomile, lavender, rosemary, camphor, mountain-pine, mint, tea tree and eucalyptus. The amount of the ethereal oils in the preparation of the present invention is preferably 0 to 70 percent by weight, more preferably 3 to 50 percent by weight, based on the sum of all components in the.preparation. The ethereal oils are preferably added in a pure form or in the form of extracts or cold-drawn and warm-drawn oils.
The preparation of the present invention can contain all known amino acids and amino acid derivatives. Preferred amino acids and amino acid derivatives are alanine, phenylalanine, cysteine, cystine, proline, tyrosine, serine, histidine, glycin, leucine, isoleucine, valine, tryptophan, arginine, lysin, asparagine and glutamine.
Particularly cystine, cysteine, proline, serine, histidine, lycine, leucine, isoleucine, valine, tyrosine, arginine, lysin, asparagine and glutamine are used. Cystine, histidine, glycin, leucine, valine, arginine, lysin and glutamine are especially preferred. The D-form, DL-form and L-form of the amino acids can be used, whereby the L-form is preferred. Examples for amino acid derivatives are N-acetylated forms, e.g. N-acetyl-L-glutamine, N-acetyl-L-tyrosine and N-acetyl-DL-tryptophan. The amino acids and amino acid derivatives can be used solely or in the form of mixtures. The amount of amino acids and amino acid derivatives in the preparation of the present invention is preferably 0.1 to 40 percent by weight, more preferably 0.2 to 30 percent by weight, most preferably 0.2 to 15 percent by weight, based on the sum of all components in the preparation. The amino acids and their derivatives are preferably added in a pure form.
The preparations of the present invention are furthermore characterized by the presence of zinc oxide and/or an inorganic peroxide. As inorganic peroxides preferably zinc peroxide, sodium peroxide, potassium peroxide, calcium peroxide or magnesium peroxide are used. Zinc oxide and/or an inorganic peroxide, for example, can be used to regulate the osmotic pressure. Surprisingly, the combination of amino acids with zinc oxide and/or an inorganic peroxide has a particularly good effect, compared to the use of magnesium peroxide alone. The total amount of zinc oxide and inorganic peroxide in the preparation of the present invention is preferably 0.5 to 50 percent by weight, more preferably 1.5 to 40 percent by weight, based on the sum of all components in the preparation. The amount of inorganic peroxide, if applied topically, should preferably not be larger than 10 percent by weight, more preferably not larger than 6 percent by weight, most preferably not larger than 3 percent by weight, and, if applied internally, not larger than 20 percent by weight, more preferably not larger than 15 percent by weight. Zinc oxide and inorganic peroxide are preferably added in a pure form.
Optionally, tego-betaine can additionally be present in the preparation of the present invention. The amount of tego-betaine in the inventive preparation is preferably 0 to 25 percent by weight, more preferably 1 to 20 percent by weight and most preferably 5 to 10 percent by weight based on the sum of all components in the preparation.
Optionally, the preparation of the present invention can contain all known bioactive plant substances, also called secondary plant substances. The secondary plant substances used in the present invention particularly comprise carotinoids, phytosterols, saponins, polyphenols, flavonoids, terpenes, phytoestrogens, sulfides, phytin acid and dietary fiber. Of the above-mentioned bioactive plant substances particularly the polyphenols, the flavonoids and the bioflavonoids are used in the present invention. Bioflavonoids of natural sources are especially preferred in the inventive preparation. The bioactive plant substances can be present in the preferred embodiments of the preparation in a preferred amount of 0 to 75 percent by weight, more preferably 2 to 50 percent by weight, based on the sum of all components in the preparation. Preferred natural sources for the bioflavonoids are vegetables, such as pulses, carrots, tomatoes, broccoli and paprika, corn, sesame, citrus fruits, green and black tea, St.
John's wort, grapes, etc. The bioactive plant substances are preferably added in the form of extracts.
Optionally, all known unsaturated fatty acids can additionally be used in the preparation of the present invention. Preferably unsaturated fatty acids that are included in vegetable and animal oils (such as fish oil) are used.
Polyunsaturated fatty acids from vegetable sources are essential precursors of important regulators of metabolism (eicosanoids and prostaglandines). The amount of unsaturated fatty acids in the inventive preparation is preferably 0 to 70 percent by weight, more preferably 2 to 45 percent by weight, based on the sum of all components in the preparation. Examples for preferred pure vegetable sources of unsaturated fatty acids are evening primrose oil, flax oil, olive oil, wheat germ oil, soy oil, sunflower oil, borage oil, pumpkin seed oil and oil of the seeds of the redcurrant. The unsaturated fatty acids are preferably added in the form of cold-drawn oils.
Optionally, the preparation of the present invention can furthermore additionally contain usual liposomes, lecithin and lipodermine. Liposomes are important, as they control the release of vitamin A and vitamin E. That way these vitamins are accessible over a longer period of time. The amount of liposomes, lecithin or lipodermine in the inventive preparation is preferably 0 to 30 percent by weight, more preferably 2 to 20 percent by weight, based on the sum of all components in the preparation.
Optionally, the preparation of the present invention can additionally comprise epigallocatechines, preferably recovered from green tea. Through epigallocatechines the aging of the cells can be delayed. Furthermore, they are important as cosubstances and serve to support the effect of micro nutrients, such as vitamins. The amount of the epigallocatechines in the preparation is preferably 0 to 60 percent by weight, more preferably 2 to 30 percent by weight, based on the sum of all components in the preparation. The epigallocatechines are preferably added in a pure form or as extracts.
Optionally, the preparation of the present invention can additionally comprise all known representatives of vitamins and provitamins. Particularly vitamins A, those of the B-complex, C, D and E and P-carotine are preferably used in the preparation. The amount of the vitamins in the preparation of the present invention is preferably 0 to 75 percent by weight, more preferably 5 to 50 percent by weight, based on the sum of all components in the preparation. The vitamins are added both in a natural form as extracts and in a synthetic form (e.g. B-vitamins), whereby differences in the effect of the vitamins are not linked with this fact.
Optionally, the preparation of the present invention can additionally comprise antifungal and antimicrobial components. Antibiotics, bacteriostatics, corticosteroids, cortisones, econazol nitrate, dexametasone, hydroxy benzoate, etc. can be added to the inventive preparation. The amount of the antifungal and antimicrobial components in the preparation is preferably 0 to 60 percent by weight and most preferably 2 to 30 percent by weight, based on the sum of all components in the preparation.
Optionally, the preparation of the present invention can comprise all known adjuvants, additives and carrier substances, the usual binding and adhesive agents and solvents. Preferred examples are milk fat, unhydrogenated, partly hydrogenated or hydrogenated soy fat, soy oil, walnut butter, glycerin, gelatin, pectin, lecithin, P-carotenes, sorbitol solution, iron oxide, titanium dioxide, dyes, fats, waxes, emulgators (e.g. IRICALMIN of the company Pentafarm Ltd., CH), silicones, polyethylenes, polysorbitones, (meth)acryl compounds, talcum, dragantum, xanthan-gum, starch, vaseline, dextrose, saccharin, paraffins, acids, preservatives and fragrances. For example pectin can be used as binding and adhesive agent. Usual amounts of the above-mentioned substances and agents are used, e.g. pectin up to an amount of 10 percent by weight, based on the sum of all components in the preparation.
The preparation of the present invention can be prepared in the usual manner known to every person skilled in the art, for example by combining the active ingredients with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and optionally the usual additives, adjuvants and solvents to a galenic form of administration. Methods for manufacturing galenic forms of administration, such as ointments and cremes, are for example described in H.
Sucker, B. Fuchs, P. Speiser, "Pharmazeutische Technologie", 2"d edition (1991), Georg Thieme Verlag Stuttgart; R. Voigt, "Lehrbuch der pharmazeutischen Technologie", Thieme Verlag, 1976. For the preparation of the present invention all known forms of application are possible. Preferred forms of application are creme, ointment, paste, emulsion, lotion, fluid, solution, gel, powder, spray, gelatin, foam and the like. Forms of application for internal application are for example capsules, tablets, coated tablets, drinking solutions and injection solutions, for example for hypodermal injections. A depot form as form of application is possible as well.
In principle, all known modes of application are possible for the preparation of the present invention. The most preferred one is the topical application, for example effected by applying a corresponding form of application to the skin, e.g. by applying, rubbing on, rubbing gently in, spraying on, dabbing on, etc.
Application is also poSsible in the form of ointment bandages or hypodermal injections.
The preparation of the present invention can be applied once or several times a day and both over short and long periods of time. However, the daily dose and the frequency of the application per day depends on the recipe of the individual inventive preparation.
Depending on the recipe, the preparations of the present invention are suitable as food supplement, cosmetic or pharmaceutical composition, preferably as topical cosmetic or as topical pharmaceutical composition to be applied on the skin and tissue of mammals, and are for example used for the care, protection and _ prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue. Depending on their recipe, they are in a preferred embodiment particularly applicable to all skin irritations (e.g. disturbed skin physiology, sun burn), cellulitis, wrinkles, acne, herpes, psoriasis, neurodermatitis, ozone damage, burns, caustic burns, cellular metabolic disturbances and other modifications with accumulation of tissue fluid, fat and other cellular products and cellular catabolites, such as thickenings, edemas, hematomas, and are furthermore applicable to, for example, hemorrhoids, rheumatism, arthrosis, and skin cancer.
The preparation can also be applied to mucous membranes, e.g. in the digestive system.
The present invention is further illustrated by an example.
Example 1 A preparation according to the invention having the following components was prepared in the usual manner:
Zinc oxide 8 wt.-%
Sodium peroxide 3 wt.-%
Sodium phosphate 10 wt.-%
Calcium phosphate 6 wt.-%
Calcium chloride 5 wt.-%
Arginine 7 wt.-%
Leucine 8 wt.-%
Asparagine 5.5 wt.-%
Valine 2 wt.-%
Hamamelis 1 wt.-%
Tannin 3 wt.-%
Pectin 1 wt.-%
Tego-betaine 2 wt.-%
Vitamin A 1 wt.-%
=Vitamin E 1.5 wt.-%
P-carotine 0.5 wt.-%
Collagen 1.5 wt.-%
Aloe Vera 2 wt.-%
Olive oil 2 wt.-%
Carotinoids 2 wt.-%
Gelatin 1 wt.-%
Liposomes 2 wt.-%
Purified water ad 100 wt.-%
The composition of the above example was applied to one leg of probands. To the other leg control substances (placebo substances; control leg) are applied. The results of the examinations can be summarized as follows:
As acute reaction of the above inventive recipe an increase of microcirculation was found=. After about 50 minutes a significant improvement of microcirculation was observed, whereby a maximum increase was reached after about 100 minutes. The significant effective phase was observed after about 120 minutes.
On the control leg no changes in microcirculation were observed. As a further reaction caused by the application of the inventive recipe, a reduction of the fat layer on the treated leg could be observed, while there was no modification on the control leg. Through these examinations it was shown that the inventive preparation can significantly improve microcirculation and reduce the fat layer.
Example 2 Amount (wt.-%) Aspargine 0.30 Leucine 0.20 Valine 0.30 Arginine 0.20 Zinc peroxide 0.50 Calcium phosphate 4.50 Sodium phosphate 3.50 Zinc oxide transparent 2.00 Calcium chloride 4.00 Magnesium sulfate 3.00 Distilled water 62.90 Hamamelis 2.50 Tego-betaine 2.00 Sorbitol 6.00 Rosemary oil 0.30 Menthol 0.30 Green tea pulvis 1.00 Ivy/bottlebrush (horsetail)/algae/green tea 5.00 Xanthan-gum 1.50 The above inventive preparation was prepared in the usual manner.
First, microcirculation on a specific skin area of a proband was measured.
After that, the recipe of example 2 was rubbed gently into this skin area.
Microcirculation was measured immediately and, after that, every half hour over a period of 4 hours. Hereby microcirculation was measured in flux units. The measuring results were plotted in relation to time. In comparison with a commercially available product which comprises salts and magnesium peroxide and which was, like the inventive preparation, applied to another skin area, it was observed that microcirculation rose earlier, maintained a higher level over a longer period of time and flattened to the starting value much later when the inventive recipe comprising a combination of certain amino acids and zinc oxide and zinc peroxide was used. The improvement compared to the commercial product was between 7 and 15 % at the corresponding measuring points. The results show the improved systemic, synergistic effect of the inventive recipe compared to the commercial product.
Example 3 A preparation according to the invention having the following components was prepared in the usual manner:
Amount (wt.-%) Distilled water 71.15 Calcium phosphate 1.50 Leucine 0.20 Valine 0.30 Arginine 0.20 Aspargine 0.30 Zinc peroxide 0.25 Sodium phosphate 1.50 Zinc oxide,transparent 3.00 Karion FP liquid 4.00 Neo Dragold liquid 0.30 Calcium chloride 1.50 Magnesium sulfate 2.50 Green tea pulvis 2.00 Calendula 3.00 Hamamelis 2.50 St. John's wort 3.00 Fragrance 1677 0.30 Teatree oil Australian 1.00 Xanthan-gum 1.50 Example 4 A preparation according to the invention having the following components was prepared in the usual manner:
Amount (wt.-%) Distilled water 66.70 Zinc oxide transparent 2.00 Sodium phosphate 3.00 Aspargine 0.05 Calcium phosphate 3.50 Calcium chloride 3.50 Leucine 0.20 Magnesium sulfate 3.00 Zinc peroxide 0.30 Tego-betaine 2.00 Hamamelis 2.50 Sorbitol 5.00 YLANG-YLANG OIL II 0.10 Lotus fragrance - ethereal oil mixture 0.10 Menthol 0.05 Green tea.pulvis 0.50 IRICALMIN 3.00 GLYCODERM 3.00 Xanthan-gum 1.50 In further applications of recipes which are part of the invention, significantly positive effects regarding aging, elasticity, moisture, wrinkling and tightening of the skin were observed.
Falbe and M. Regitz, keyword "amino acids", Thieme Verlag, 1996 and bibliographic references cited therein.
Liposomes are particles surrounded by single or multi-layered phospholipid double membranes which can be loaded with hydrophilic pharmaceutical molecules in the inner, aqueous phase. By using them as pharmaceutical carriers, a selective local enrichment of active substances and a delayed release of active substances can be achieved.
Numerous preparations for treating and preventing mycotic, microbic, pathologic and other tissue-damaging manifestations and effects, tissue modifications, tissue deformations and cellular metabolic disturbance and other forms of damage to human tissue are commercially available. There are, for example, various therapeutic approaches for treating skin and connective tissue problems. The success of many of these preparations is, however, questionable, as these preparations are unable to reach the damaged cells and/or to act in the damaged cells. Furthermore, many of the products that are commercially available do not take the active mechanism discovered by scientists into account in which the cell is remineralized in a natural way and metabolism is stimulated so that the natural inner pressure of the cell is reestablished, the cell volume is normalized and fat and slag substances are effectively displaced and secreted.
DE-OS-196 22 708 describes a phytobiological preparation for the topical and parenteral incorporal application for preventing, caring for and treating various pathological and other endogenic and exogenic effects, modifications and diseases, as well as for maintaining, healing and reestablishing the homeostasis in and at animal and human organs and soft tissue, characterized in that it contains the following components:
(a) one or more ion-containing components and mineral salts, (b) one or more adstringent components, one or more binding agents, a humectant and one or more ethereal oils, and (c) optionally one or more vegetable extracts, a gelling agent, acid bondings, hyaluronidase or other suitable components in an amount between 0.01 and 20%. This preparation can optionally contain calendula, hamamelis or other homeopathic components, amino acids, enzymes, vitamins, electrolytes, dyes, wax, emulgators, starch, vaseline, paraffines, oils, acids, fats, vegetable mixtures and extracts, urea, sulfate compounds, etc. Neither does the patent application disclose examples of amino acids nor are amino acids used in the examples.
An object'of the present invention is to provide a skin and tissue care and/or treatment preparation which distinguishes itself by a quick effect, excellent tolerance, a broad field of application and particularly intense deep action.
In particular, the preparation is supposed to be applicable for care, protection, prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue. The preparation according to the invention is supposed to take into account research results concerning the diffusion of ions through ion channels into the intracellular space and improve microcirculation in the cell.
An object of the present invention is solved by the provision of a composition comprising the following components:
(a) at least one salt selected from alkali and alkaline earth metal salts and other minerals, characterized in that it contains (b) at Ieast one amino acid, and (c) zinc oxide and/or an inorganic peroxide.
Preferably zinc oxide, magnesium peroxide or sodium peroxide are used as component (c) of the composition.
In preferred embodiments the inventive preparation can additionally comprise, each independent of the other, at least one adstringent agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as flavonoids and epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and antimicrobial components. Furthermore, it can comprise usual carriers and adjuvants as well as binding and adhesive agents and usual solvents.
In a preferred embodiment the preparation of the present invention is topically used through direct application at the site of action.
The preparation of the present invention takes into account new research results concerning the diffusion of ions through ion channels into the intracellular space.
Hereby ions of mineral salts penetrate through the upper skin layers deep into the cell interior of hypoderm, connective tissue and fat cells. The inventive preparation uses i.a. the principle of ion exchange between cell interior and cell exterior using high osmotic pressure which is created by the combination of active substances of the preparation. In this process, however, the amino acids, which help the ions to more effectively overcome the natural barriers of the cell membranes to reach the cell interior, which is the actual site of action, play an important role.
The inventive composition is in particular still effective if the functional capability of the cell regarding ion activity is limited. Particularly when the ion activity is limited, the amino acids act as additional carriers for substances which must be infiltrated for the intracellular activity in order to be functionally effective therein.
It has been found that the combination of amino acids and zinc oxide and/or inorganic peroxides improves the microcirculation in the cell, compared to the use of salts.
The improvement can visually and biometrically be shown. If only salts are used, an increase of the microcirculation in the cell abruptly falls back to the starting value after about 1.5 hours. When the inventive composition comprising the combination of amino acids and zinc oxide and/or inorganic peroxides is used, the improvement of microcirculation is, compared to the use of salt, greater, more steady, lasts longer and approaches the starting value slowly. This allows a better infiltration of agents into and a better distribution of agents in the cell, which increases the synergistic effect.
Furthermore, in contrast to the salts alone, a combination of salts and amino acids has a greater positive effect on the skin physiology. This affects in particular the moisturing, factor, the pH value and the sebometry of the skin. When salts are used in combination with amino acids, the salts are infiltrated into the cell more effectively than without amino acids, as amino acids are, on the one hand, a key for the cell membranes and, on the other hand, support and increase the activation of the ion channels.
Alkali and alkaline earth metal salts and other minerals are essential regulators in the metabolism. In the present invention all known alkali and alkaline earth metal salts and minerals, which can also be present as trace elements, can be used.
Preferred representatives of the group of alkali and alkaline earth metal salts and minerals that can be used in the present invention are sodium, potassium, magnesium, calcium, silicon, zinc, manganese, copper, iron, fluorine, chlorine, bromine, iodine and phosphorus. Preferred trace elements are accidental trace elements, such as silver, gold, aluminum, barium, bismuth, cadmium, chrome, nickel, lead, tin, titanium and vanadium, and essential trace elements, such as chrome, cobalt, copper, fluorine, iron, iodine, manganese, molybdenum and selenium, which are present in, for example, enzymes, chromoproteines and hormones as constituents. The amount of the alkali and alkaline earth metal salts and other minerals in the inventive preparation is preferably 10 to 90 percent by weight, more preferably 20 to 85 percent by weight, particularly in topically applicable agents 10 to 30 percent by weight, more preferably 10 to 25 percent by weight, based on the sum of all components in the preparation, depending on the desired osmotic effect. The alkali and alkaline earth metal salts and the other minerals are added in the form of usual salt compounds or organic compounds.
For example, sodium, potassium and magnesium are preferably added in the form of their chloride salts, sodium and calcium in the form of phosphates.
The adstringent agents which are optionally used in the present invention comprise usual compounds for this purpose. Tannin, hamamelis, rhubarb, rhatany, and salvia are preferably used as adstringent. The amount of the adstringent agents in the inventive preparation is preferably 0 to 30 percent by weight, more preferably 1 to 25 percent by weight, based on the sum of all components in the preparation. The adstringent agents are preferably added in a pure form.
In the present invention usual humectants can optionally be used. Preferred humectants are glycerin, aloe vera, collagen, desamidocollagen, collagen hydrolysates, elastin hydrolysates, hyalomucco solution, fibrostimulin, PN 73, Q 10, water, aloe barbadensis gel, camelia sinensis extract, hedera helix, matricaria (camomile recutita) oil and butylene glykol. The amount of the humectants in the inventive preparation is preferably 0 to 70 percent by weight, more preferably 5 to 50 percent by weight, based on the sum of all components in the preparation.
Furthermore, the preparation of the present invention can optionally comprise usual ethereal oils. Preferred ethereal oils are oils of camomile, lavender, rosemary, camphor, mountain-pine, mint, tea tree and eucalyptus. The amount of the ethereal oils in the preparation of the present invention is preferably 0 to 70 percent by weight, more preferably 3 to 50 percent by weight, based on the sum of all components in the.preparation. The ethereal oils are preferably added in a pure form or in the form of extracts or cold-drawn and warm-drawn oils.
The preparation of the present invention can contain all known amino acids and amino acid derivatives. Preferred amino acids and amino acid derivatives are alanine, phenylalanine, cysteine, cystine, proline, tyrosine, serine, histidine, glycin, leucine, isoleucine, valine, tryptophan, arginine, lysin, asparagine and glutamine.
Particularly cystine, cysteine, proline, serine, histidine, lycine, leucine, isoleucine, valine, tyrosine, arginine, lysin, asparagine and glutamine are used. Cystine, histidine, glycin, leucine, valine, arginine, lysin and glutamine are especially preferred. The D-form, DL-form and L-form of the amino acids can be used, whereby the L-form is preferred. Examples for amino acid derivatives are N-acetylated forms, e.g. N-acetyl-L-glutamine, N-acetyl-L-tyrosine and N-acetyl-DL-tryptophan. The amino acids and amino acid derivatives can be used solely or in the form of mixtures. The amount of amino acids and amino acid derivatives in the preparation of the present invention is preferably 0.1 to 40 percent by weight, more preferably 0.2 to 30 percent by weight, most preferably 0.2 to 15 percent by weight, based on the sum of all components in the preparation. The amino acids and their derivatives are preferably added in a pure form.
The preparations of the present invention are furthermore characterized by the presence of zinc oxide and/or an inorganic peroxide. As inorganic peroxides preferably zinc peroxide, sodium peroxide, potassium peroxide, calcium peroxide or magnesium peroxide are used. Zinc oxide and/or an inorganic peroxide, for example, can be used to regulate the osmotic pressure. Surprisingly, the combination of amino acids with zinc oxide and/or an inorganic peroxide has a particularly good effect, compared to the use of magnesium peroxide alone. The total amount of zinc oxide and inorganic peroxide in the preparation of the present invention is preferably 0.5 to 50 percent by weight, more preferably 1.5 to 40 percent by weight, based on the sum of all components in the preparation. The amount of inorganic peroxide, if applied topically, should preferably not be larger than 10 percent by weight, more preferably not larger than 6 percent by weight, most preferably not larger than 3 percent by weight, and, if applied internally, not larger than 20 percent by weight, more preferably not larger than 15 percent by weight. Zinc oxide and inorganic peroxide are preferably added in a pure form.
Optionally, tego-betaine can additionally be present in the preparation of the present invention. The amount of tego-betaine in the inventive preparation is preferably 0 to 25 percent by weight, more preferably 1 to 20 percent by weight and most preferably 5 to 10 percent by weight based on the sum of all components in the preparation.
Optionally, the preparation of the present invention can contain all known bioactive plant substances, also called secondary plant substances. The secondary plant substances used in the present invention particularly comprise carotinoids, phytosterols, saponins, polyphenols, flavonoids, terpenes, phytoestrogens, sulfides, phytin acid and dietary fiber. Of the above-mentioned bioactive plant substances particularly the polyphenols, the flavonoids and the bioflavonoids are used in the present invention. Bioflavonoids of natural sources are especially preferred in the inventive preparation. The bioactive plant substances can be present in the preferred embodiments of the preparation in a preferred amount of 0 to 75 percent by weight, more preferably 2 to 50 percent by weight, based on the sum of all components in the preparation. Preferred natural sources for the bioflavonoids are vegetables, such as pulses, carrots, tomatoes, broccoli and paprika, corn, sesame, citrus fruits, green and black tea, St.
John's wort, grapes, etc. The bioactive plant substances are preferably added in the form of extracts.
Optionally, all known unsaturated fatty acids can additionally be used in the preparation of the present invention. Preferably unsaturated fatty acids that are included in vegetable and animal oils (such as fish oil) are used.
Polyunsaturated fatty acids from vegetable sources are essential precursors of important regulators of metabolism (eicosanoids and prostaglandines). The amount of unsaturated fatty acids in the inventive preparation is preferably 0 to 70 percent by weight, more preferably 2 to 45 percent by weight, based on the sum of all components in the preparation. Examples for preferred pure vegetable sources of unsaturated fatty acids are evening primrose oil, flax oil, olive oil, wheat germ oil, soy oil, sunflower oil, borage oil, pumpkin seed oil and oil of the seeds of the redcurrant. The unsaturated fatty acids are preferably added in the form of cold-drawn oils.
Optionally, the preparation of the present invention can furthermore additionally contain usual liposomes, lecithin and lipodermine. Liposomes are important, as they control the release of vitamin A and vitamin E. That way these vitamins are accessible over a longer period of time. The amount of liposomes, lecithin or lipodermine in the inventive preparation is preferably 0 to 30 percent by weight, more preferably 2 to 20 percent by weight, based on the sum of all components in the preparation.
Optionally, the preparation of the present invention can additionally comprise epigallocatechines, preferably recovered from green tea. Through epigallocatechines the aging of the cells can be delayed. Furthermore, they are important as cosubstances and serve to support the effect of micro nutrients, such as vitamins. The amount of the epigallocatechines in the preparation is preferably 0 to 60 percent by weight, more preferably 2 to 30 percent by weight, based on the sum of all components in the preparation. The epigallocatechines are preferably added in a pure form or as extracts.
Optionally, the preparation of the present invention can additionally comprise all known representatives of vitamins and provitamins. Particularly vitamins A, those of the B-complex, C, D and E and P-carotine are preferably used in the preparation. The amount of the vitamins in the preparation of the present invention is preferably 0 to 75 percent by weight, more preferably 5 to 50 percent by weight, based on the sum of all components in the preparation. The vitamins are added both in a natural form as extracts and in a synthetic form (e.g. B-vitamins), whereby differences in the effect of the vitamins are not linked with this fact.
Optionally, the preparation of the present invention can additionally comprise antifungal and antimicrobial components. Antibiotics, bacteriostatics, corticosteroids, cortisones, econazol nitrate, dexametasone, hydroxy benzoate, etc. can be added to the inventive preparation. The amount of the antifungal and antimicrobial components in the preparation is preferably 0 to 60 percent by weight and most preferably 2 to 30 percent by weight, based on the sum of all components in the preparation.
Optionally, the preparation of the present invention can comprise all known adjuvants, additives and carrier substances, the usual binding and adhesive agents and solvents. Preferred examples are milk fat, unhydrogenated, partly hydrogenated or hydrogenated soy fat, soy oil, walnut butter, glycerin, gelatin, pectin, lecithin, P-carotenes, sorbitol solution, iron oxide, titanium dioxide, dyes, fats, waxes, emulgators (e.g. IRICALMIN of the company Pentafarm Ltd., CH), silicones, polyethylenes, polysorbitones, (meth)acryl compounds, talcum, dragantum, xanthan-gum, starch, vaseline, dextrose, saccharin, paraffins, acids, preservatives and fragrances. For example pectin can be used as binding and adhesive agent. Usual amounts of the above-mentioned substances and agents are used, e.g. pectin up to an amount of 10 percent by weight, based on the sum of all components in the preparation.
The preparation of the present invention can be prepared in the usual manner known to every person skilled in the art, for example by combining the active ingredients with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and optionally the usual additives, adjuvants and solvents to a galenic form of administration. Methods for manufacturing galenic forms of administration, such as ointments and cremes, are for example described in H.
Sucker, B. Fuchs, P. Speiser, "Pharmazeutische Technologie", 2"d edition (1991), Georg Thieme Verlag Stuttgart; R. Voigt, "Lehrbuch der pharmazeutischen Technologie", Thieme Verlag, 1976. For the preparation of the present invention all known forms of application are possible. Preferred forms of application are creme, ointment, paste, emulsion, lotion, fluid, solution, gel, powder, spray, gelatin, foam and the like. Forms of application for internal application are for example capsules, tablets, coated tablets, drinking solutions and injection solutions, for example for hypodermal injections. A depot form as form of application is possible as well.
In principle, all known modes of application are possible for the preparation of the present invention. The most preferred one is the topical application, for example effected by applying a corresponding form of application to the skin, e.g. by applying, rubbing on, rubbing gently in, spraying on, dabbing on, etc.
Application is also poSsible in the form of ointment bandages or hypodermal injections.
The preparation of the present invention can be applied once or several times a day and both over short and long periods of time. However, the daily dose and the frequency of the application per day depends on the recipe of the individual inventive preparation.
Depending on the recipe, the preparations of the present invention are suitable as food supplement, cosmetic or pharmaceutical composition, preferably as topical cosmetic or as topical pharmaceutical composition to be applied on the skin and tissue of mammals, and are for example used for the care, protection and _ prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue. Depending on their recipe, they are in a preferred embodiment particularly applicable to all skin irritations (e.g. disturbed skin physiology, sun burn), cellulitis, wrinkles, acne, herpes, psoriasis, neurodermatitis, ozone damage, burns, caustic burns, cellular metabolic disturbances and other modifications with accumulation of tissue fluid, fat and other cellular products and cellular catabolites, such as thickenings, edemas, hematomas, and are furthermore applicable to, for example, hemorrhoids, rheumatism, arthrosis, and skin cancer.
The preparation can also be applied to mucous membranes, e.g. in the digestive system.
The present invention is further illustrated by an example.
Example 1 A preparation according to the invention having the following components was prepared in the usual manner:
Zinc oxide 8 wt.-%
Sodium peroxide 3 wt.-%
Sodium phosphate 10 wt.-%
Calcium phosphate 6 wt.-%
Calcium chloride 5 wt.-%
Arginine 7 wt.-%
Leucine 8 wt.-%
Asparagine 5.5 wt.-%
Valine 2 wt.-%
Hamamelis 1 wt.-%
Tannin 3 wt.-%
Pectin 1 wt.-%
Tego-betaine 2 wt.-%
Vitamin A 1 wt.-%
=Vitamin E 1.5 wt.-%
P-carotine 0.5 wt.-%
Collagen 1.5 wt.-%
Aloe Vera 2 wt.-%
Olive oil 2 wt.-%
Carotinoids 2 wt.-%
Gelatin 1 wt.-%
Liposomes 2 wt.-%
Purified water ad 100 wt.-%
The composition of the above example was applied to one leg of probands. To the other leg control substances (placebo substances; control leg) are applied. The results of the examinations can be summarized as follows:
As acute reaction of the above inventive recipe an increase of microcirculation was found=. After about 50 minutes a significant improvement of microcirculation was observed, whereby a maximum increase was reached after about 100 minutes. The significant effective phase was observed after about 120 minutes.
On the control leg no changes in microcirculation were observed. As a further reaction caused by the application of the inventive recipe, a reduction of the fat layer on the treated leg could be observed, while there was no modification on the control leg. Through these examinations it was shown that the inventive preparation can significantly improve microcirculation and reduce the fat layer.
Example 2 Amount (wt.-%) Aspargine 0.30 Leucine 0.20 Valine 0.30 Arginine 0.20 Zinc peroxide 0.50 Calcium phosphate 4.50 Sodium phosphate 3.50 Zinc oxide transparent 2.00 Calcium chloride 4.00 Magnesium sulfate 3.00 Distilled water 62.90 Hamamelis 2.50 Tego-betaine 2.00 Sorbitol 6.00 Rosemary oil 0.30 Menthol 0.30 Green tea pulvis 1.00 Ivy/bottlebrush (horsetail)/algae/green tea 5.00 Xanthan-gum 1.50 The above inventive preparation was prepared in the usual manner.
First, microcirculation on a specific skin area of a proband was measured.
After that, the recipe of example 2 was rubbed gently into this skin area.
Microcirculation was measured immediately and, after that, every half hour over a period of 4 hours. Hereby microcirculation was measured in flux units. The measuring results were plotted in relation to time. In comparison with a commercially available product which comprises salts and magnesium peroxide and which was, like the inventive preparation, applied to another skin area, it was observed that microcirculation rose earlier, maintained a higher level over a longer period of time and flattened to the starting value much later when the inventive recipe comprising a combination of certain amino acids and zinc oxide and zinc peroxide was used. The improvement compared to the commercial product was between 7 and 15 % at the corresponding measuring points. The results show the improved systemic, synergistic effect of the inventive recipe compared to the commercial product.
Example 3 A preparation according to the invention having the following components was prepared in the usual manner:
Amount (wt.-%) Distilled water 71.15 Calcium phosphate 1.50 Leucine 0.20 Valine 0.30 Arginine 0.20 Aspargine 0.30 Zinc peroxide 0.25 Sodium phosphate 1.50 Zinc oxide,transparent 3.00 Karion FP liquid 4.00 Neo Dragold liquid 0.30 Calcium chloride 1.50 Magnesium sulfate 2.50 Green tea pulvis 2.00 Calendula 3.00 Hamamelis 2.50 St. John's wort 3.00 Fragrance 1677 0.30 Teatree oil Australian 1.00 Xanthan-gum 1.50 Example 4 A preparation according to the invention having the following components was prepared in the usual manner:
Amount (wt.-%) Distilled water 66.70 Zinc oxide transparent 2.00 Sodium phosphate 3.00 Aspargine 0.05 Calcium phosphate 3.50 Calcium chloride 3.50 Leucine 0.20 Magnesium sulfate 3.00 Zinc peroxide 0.30 Tego-betaine 2.00 Hamamelis 2.50 Sorbitol 5.00 YLANG-YLANG OIL II 0.10 Lotus fragrance - ethereal oil mixture 0.10 Menthol 0.05 Green tea.pulvis 0.50 IRICALMIN 3.00 GLYCODERM 3.00 Xanthan-gum 1.50 In further applications of recipes which are part of the invention, significantly positive effects regarding aging, elasticity, moisture, wrinkling and tightening of the skin were observed.
Claims (15)
1. Use of a preparation comprising:
(a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) at least one amino acid, and (c) zinc oxide and/or an inorganic peroxide for the preparation of a pharmaceutical composition for the topical treatment of skin irritations, sun burn, cellulitis, wrinkles, acne, herpes, neurodermatitis, ozone damage, burns, caustic burns, thickenings, edemas and hematomas.
(a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) at least one amino acid, and (c) zinc oxide and/or an inorganic peroxide for the preparation of a pharmaceutical composition for the topical treatment of skin irritations, sun burn, cellulitis, wrinkles, acne, herpes, neurodermatitis, ozone damage, burns, caustic burns, thickenings, edemas and hematomas.
2. Preparation for topical application comprising the following components:
(a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) at least one amino acid, (c) zinc oxide and/or an inorganic peroxide, and (d) at least one secondary plant substance selected from the group consisting of carotinoids, phytosterols, saponins, polyphenols, flavonoids, terpenes, phytoestrogens, sulfides, phytin acid, and combinations thereof.
(a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) at least one amino acid, (c) zinc oxide and/or an inorganic peroxide, and (d) at least one secondary plant substance selected from the group consisting of carotinoids, phytosterols, saponins, polyphenols, flavonoids, terpenes, phytoestrogens, sulfides, phytin acid, and combinations thereof.
3. Preparation for topical application comprising the following components:
(a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) at least one amino acid, (c) zinc oxide and/or an inorganic peroxide, (d) at least one secondary plant substance selected from the group consisting of carotinoids, phytosterols, saponins, polyphenols, flavonoids, terpenes, phytoestrogens, sulfides, phytin acid, and combinations thereof, and (e) at least one polyunsaturated fatty acid of vegetable sources.
(a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) at least one amino acid, (c) zinc oxide and/or an inorganic peroxide, (d) at least one secondary plant substance selected from the group consisting of carotinoids, phytosterols, saponins, polyphenols, flavonoids, terpenes, phytoestrogens, sulfides, phytin acid, and combinations thereof, and (e) at least one polyunsaturated fatty acid of vegetable sources.
4. Preparation according to claim 2, characterized in that it additionally comprises at least one unsaturated fatty acid.
5. Preparation according to any one of claims 2 to 4, characterized in that it additionally comprises tego-betaine and/or at least one epigallocatechine and/or at least one trace element.
6. Preparation according to any one of claims 2 to 5, characterized in that it additionally comprises at least one liposome and/or at least one vitamin.
7. Preparation according to any one of claims 2 to 6, characterized in that it additionally comprises at least one adstringent agent and/or at least one humectant and/or at least one ethereal oil.
8. Preparation according to any one of claims 2 to 7, characterized in that it additionally comprises antifungal and/or antimicrobial components.
9. Preparation according to any one of claims 2 to 8, characterized in that it additionally comprises at least one component selected from carrier substances, adjuvants, additives, binding agents, adhesive agents and solvents.
10. Preparation according to any one of claims 2 to 9, comprising the following components:
(a) 10 to 90 wt.-% of the salt, selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) 0.1 to 40 wt.-% of the amino acid, and (c) a total amount of zinc oxide and inorganic peroxide of 0.5 to 50 wt.-%, based on the sum of all components in the preparation.
(a) 10 to 90 wt.-% of the salt, selected from alkali metal salts, alkaline earth metal salts and other minerals, (b) 0.1 to 40 wt.-% of the amino acid, and (c) a total amount of zinc oxide and inorganic peroxide of 0.5 to 50 wt.-%, based on the sum of all components in the preparation.
11. Preparation according to any one of the claims 2 to 10, wherein:
(a) the at least one salt is selected from sodium, potassium, magnesium, calcium, silicon, zinc, manganese, copper, iron, fluorine, chlorine, bromine, iodine and phosphorus, and (b) the at least one amino acid is selected from cystine, cysteine, proline, serine, histidine, glycine, leucine, isoleucine, valine, tyrosine, arginine, lysine, asparagine and glutamine.
(a) the at least one salt is selected from sodium, potassium, magnesium, calcium, silicon, zinc, manganese, copper, iron, fluorine, chlorine, bromine, iodine and phosphorus, and (b) the at least one amino acid is selected from cystine, cysteine, proline, serine, histidine, glycine, leucine, isoleucine, valine, tyrosine, arginine, lysine, asparagine and glutamine.
12. Preparation according to any one of claims 2 to 11, characterized in that the inorganic peroxide is zinc peroxide, sodium peroxide, potassium peroxide, calcium peroxide or magnesium peroxide.
13. Use of a preparation as defined in any one of claims 3 to 12 for topical application.
14. Use of a preparation for topical application as defined in any one of claims 2 to 12 as a cosmetic for care, protection and prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue.
15. Use of a preparation as defined in any one of claims 2 to 12 for the preparation of a pharmaceutical composition for the topical treatment of skin irritations, sun burn, cellulitis, wrinkles, acne, herpes, neurodermatitis, ozone damage, burns, caustic burns, thickenings, edemas, hematomas, hemorrhoids, rheumatism, arthrosis and skin cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19831798.0 | 1998-07-15 | ||
DE19831798A DE19831798A1 (en) | 1998-07-15 | 1998-07-15 | Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement |
PCT/DE1999/002202 WO2000003689A2 (en) | 1998-07-15 | 1999-07-15 | Skin and tissue care and/or treatment agent |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2337772A1 CA2337772A1 (en) | 2000-01-27 |
CA2337772C true CA2337772C (en) | 2009-06-09 |
Family
ID=7874155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002337772A Expired - Fee Related CA2337772C (en) | 1998-07-15 | 1999-07-15 | Skin and tissue care and/or treatment agent |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1639991A3 (en) |
JP (1) | JP3917370B2 (en) |
KR (1) | KR100542606B1 (en) |
CN (1) | CN1201723C (en) |
AT (1) | ATE308968T1 (en) |
AU (1) | AU761947B2 (en) |
BR (1) | BR9912821A (en) |
CA (1) | CA2337772C (en) |
DE (3) | DE19831798A1 (en) |
DK (1) | DK1096918T3 (en) |
ES (1) | ES2252976T3 (en) |
HK (1) | HK1037958A1 (en) |
HU (1) | HUP0103236A2 (en) |
IL (1) | IL140889A0 (en) |
NO (1) | NO20010220L (en) |
PL (1) | PL345689A1 (en) |
WO (1) | WO2000003689A2 (en) |
ZA (1) | ZA200101244B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2476214C2 (en) * | 2007-05-22 | 2013-02-27 | Галдерма Ресерч Энд Девелопмент | Combination containing pyrrolidone-5-carboxylic acid and at least one compound of citrulline, arginine and asparagine, and using them for treating atopic dermatitis |
US8604081B2 (en) | 2009-06-24 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US8603519B2 (en) | 1997-09-17 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629384B2 (en) | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
DE20005402U1 (en) | 2000-03-22 | 2000-07-20 | Schilling Johann Georg | External treatment for skin redness and psoriasis |
JP4532706B2 (en) * | 2000-09-08 | 2010-08-25 | 花王株式会社 | Cosmetics |
DE10109798A1 (en) * | 2001-03-01 | 2002-09-12 | Aventis Pharma Gmbh | Food additives for treatment or prevention of symptoms of diabetes, osteoarthritis, osteoporosis, asthma, mental decline and age related eye disease |
DE10133202A1 (en) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Topical compositions containing osmolytes, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis |
DE10133203A1 (en) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Topical compositions containing catechins and/or their gallate esters, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis |
DE20209676U1 (en) | 2002-06-22 | 2002-09-26 | Stubna, Eduard, 80634 München | Tattoo removal preparations |
DE10243437A1 (en) * | 2002-09-18 | 2004-04-29 | Pm-International Ag | Cosmetic formulation |
US7480530B2 (en) | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Device for treatment of barrier membranes |
US8734421B2 (en) | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
EP1732577B1 (en) * | 2004-02-23 | 2013-04-10 | Strategic Science & Technologies, LLC | Topical delivery of l-arginine to improve body and skin appearance |
WO2005089803A2 (en) * | 2004-03-24 | 2005-09-29 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs |
AT501221A1 (en) * | 2005-01-14 | 2006-07-15 | Hermine Dr Engl | ACTIVE COMPOUND |
SG10201502232SA (en) * | 2006-03-22 | 2015-05-28 | Takasago Perfumery Co Ltd | Deodorant composition |
JP5568463B2 (en) * | 2007-04-09 | 2014-08-06 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | Oxygen generating composition for promoting cell and tissue survival in vivo |
AU2013203151B2 (en) * | 2007-04-09 | 2015-05-21 | Wake Forest University Health Sciences | Oxygen-generating compositions for enhancing cell and tissue survival in vivo |
JP5537046B2 (en) * | 2009-02-20 | 2014-07-02 | 花王株式会社 | Body rinse |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
CN102711905B (en) | 2009-11-13 | 2015-06-17 | 强生消费者公司 | Galvanic skin treatment device |
CN102688483B (en) * | 2011-03-22 | 2015-02-18 | 王成德 | Composition for treating dermatosis, preparation containing composition and preparation method thereof |
RU2457778C1 (en) * | 2011-05-11 | 2012-08-10 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации | Method of diagnosing disorder of microcirculation of small intestine in patients with diffuse peritonitis |
DE102011109868A1 (en) * | 2011-08-10 | 2013-02-14 | STERNA BIOLOGICALS GmbH & Co. KG. | Multiple emulsion |
WO2014041528A2 (en) * | 2012-09-14 | 2014-03-20 | Martin Roslain Margaret | A composition |
AU2013367193A1 (en) | 2012-12-26 | 2015-07-16 | A-Z Ltd. | Wound healing accelerator |
CN104173232A (en) * | 2014-08-06 | 2014-12-03 | 金玲 | Method for preparing beautifying fluid capable of promoting skin resistance and repairing small-invasive skin |
CN104189000A (en) * | 2014-09-12 | 2014-12-10 | 朴荣范 | Traumatism liquid medicine and preparation method thereof |
WO2016128235A1 (en) * | 2015-02-11 | 2016-08-18 | Nestec S.A. | Vitamin a composition |
CN105901703B (en) * | 2016-04-19 | 2020-03-10 | 上海海洋大学 | Marine organism type enteral nutrition preparation for burn patients |
EA038885B1 (en) | 2016-12-21 | 2021-11-02 | ЮНИЛЕВЕР АйПи ХОЛДИНГС Б.В. | Topical skin lightening additive and composition with amino acids and nicotinamide compounds |
WO2018113634A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
JP7082623B2 (en) | 2016-12-21 | 2022-06-08 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | Composition for personal care with cystine |
WO2018114745A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions comprising poorly soluble compounds |
JP7497296B2 (en) | 2018-05-23 | 2024-06-10 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | Nanoemulsion and its manufacturing method |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3861868A (en) * | 1971-03-30 | 1975-01-21 | Procter & Gamble | Dyeing human hair with oxidation dyes and arginine or a protamine protein |
DE2840498C2 (en) * | 1978-09-18 | 1980-04-10 | Walter Dr. 6700 Ludwigshafen Schweckendiek | Pharmaceutical preparations for the treatment of psoriasis |
US4283386A (en) * | 1978-10-10 | 1981-08-11 | Scott Eugene J Van | Method for hair care |
NZ223558A (en) * | 1987-02-18 | 1990-04-26 | Milor Scient Ltd | Acne treatment composition |
DE3905299C1 (en) * | 1989-02-21 | 1990-08-09 | Peter Prof. Dr.Med. 7980 Ravensburg De Klein | |
FR2651125B1 (en) * | 1989-08-23 | 1992-10-02 | Roussel Uclaf | PHARMACEUTICAL COMPOSITIONS OF THE "WATER PASTE" TYPE. |
EP0514451B1 (en) * | 1990-02-05 | 1997-01-15 | LifeScience Corporation | Dietary supplements comprising vitamins and minerals |
FR2674755B1 (en) * | 1991-04-05 | 1995-02-03 | Thorel Jean Noel | NEW IMMUNOSTIMULATORY DRUG COMPOSITIONS. |
US5681852A (en) * | 1993-11-12 | 1997-10-28 | The Procter & Gamble Company | Desquamation compositions |
FR2727014A1 (en) * | 1994-11-18 | 1996-05-24 | Rocher Yves Biolog Vegetale | COSMETIC COMPOSITION AND METHOD FOR COMBATING DEAGREABLE BODILY ODORS PRODUCED BY PERSPIRATION |
US5733535A (en) * | 1995-10-25 | 1998-03-31 | The Procter & Gamble Co. | Topical compositions containing N-acetylcysteine and odor masking materials |
US5597585A (en) * | 1995-12-26 | 1997-01-28 | Williams; Andrew H. | Vitamin/mineral composition |
DE19622708A1 (en) * | 1996-06-05 | 1997-12-11 | Tomic Dobrivoje | Aqueous compositions containing betaine |
JP2002503211A (en) * | 1996-06-27 | 2002-01-29 | ザ、プロクター、エンド、ギャンブル、カンパニー | Cosmetic composition |
-
1998
- 1998-07-15 DE DE19831798A patent/DE19831798A1/en not_active Withdrawn
-
1999
- 1999-07-15 ES ES99947221T patent/ES2252976T3/en not_active Expired - Lifetime
- 1999-07-15 AU AU60778/99A patent/AU761947B2/en not_active Ceased
- 1999-07-15 DE DE59912774T patent/DE59912774D1/en not_active Expired - Fee Related
- 1999-07-15 KR KR1020017000629A patent/KR100542606B1/en not_active IP Right Cessation
- 1999-07-15 BR BR9912821-7A patent/BR9912821A/en not_active IP Right Cessation
- 1999-07-15 HU HU0103236A patent/HUP0103236A2/en unknown
- 1999-07-15 JP JP2000559824A patent/JP3917370B2/en not_active Expired - Fee Related
- 1999-07-15 CA CA002337772A patent/CA2337772C/en not_active Expired - Fee Related
- 1999-07-15 EP EP05024131A patent/EP1639991A3/en not_active Withdrawn
- 1999-07-15 DK DK99947221T patent/DK1096918T3/en active
- 1999-07-15 DE DE19981295T patent/DE19981295D2/en not_active Expired - Lifetime
- 1999-07-15 AT AT99947221T patent/ATE308968T1/en not_active IP Right Cessation
- 1999-07-15 WO PCT/DE1999/002202 patent/WO2000003689A2/en active IP Right Grant
- 1999-07-15 EP EP99947221A patent/EP1096918B1/en not_active Expired - Lifetime
- 1999-07-15 IL IL14088999A patent/IL140889A0/en unknown
- 1999-07-15 CN CNB998098426A patent/CN1201723C/en not_active Expired - Fee Related
- 1999-07-15 PL PL99345689A patent/PL345689A1/en not_active Application Discontinuation
-
2001
- 2001-01-12 NO NO20010220A patent/NO20010220L/en unknown
- 2001-02-14 ZA ZA200101244A patent/ZA200101244B/en unknown
- 2001-11-09 HK HK01107891A patent/HK1037958A1/en not_active IP Right Cessation
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8603519B2 (en) | 1997-09-17 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
RU2476214C2 (en) * | 2007-05-22 | 2013-02-27 | Галдерма Ресерч Энд Девелопмент | Combination containing pyrrolidone-5-carboxylic acid and at least one compound of citrulline, arginine and asparagine, and using them for treating atopic dermatitis |
US9161915B2 (en) | 2009-06-24 | 2015-10-20 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US8604081B2 (en) | 2009-06-24 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US9457092B2 (en) | 2009-06-24 | 2016-10-04 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9492458B2 (en) | 2009-06-24 | 2016-11-15 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
US9498482B2 (en) | 2010-12-29 | 2016-11-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
Also Published As
Publication number | Publication date |
---|---|
KR20010070965A (en) | 2001-07-28 |
CN1313753A (en) | 2001-09-19 |
DE19831798A1 (en) | 2000-01-27 |
AU761947B2 (en) | 2003-06-12 |
HK1037958A1 (en) | 2002-03-01 |
BR9912821A (en) | 2001-05-02 |
IL140889A0 (en) | 2002-02-10 |
NO20010220D0 (en) | 2001-01-12 |
ES2252976T3 (en) | 2006-05-16 |
WO2000003689A2 (en) | 2000-01-27 |
DK1096918T3 (en) | 2006-01-09 |
DE19981295D2 (en) | 2001-08-30 |
CA2337772A1 (en) | 2000-01-27 |
EP1096918A2 (en) | 2001-05-09 |
PL345689A1 (en) | 2002-01-02 |
JP2002520348A (en) | 2002-07-09 |
HUP0103236A2 (en) | 2002-02-28 |
JP3917370B2 (en) | 2007-05-23 |
ATE308968T1 (en) | 2005-11-15 |
EP1639991A2 (en) | 2006-03-29 |
EP1639991A3 (en) | 2007-09-05 |
WO2000003689A3 (en) | 2000-04-20 |
EP1096918B1 (en) | 2005-11-09 |
DE59912774D1 (en) | 2005-12-15 |
KR100542606B1 (en) | 2006-01-11 |
CN1201723C (en) | 2005-05-18 |
ZA200101244B (en) | 2003-05-14 |
AU6077899A (en) | 2000-02-07 |
NO20010220L (en) | 2001-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2337772C (en) | Skin and tissue care and/or treatment agent | |
JP2002520348A5 (en) | ||
US8017138B2 (en) | Composition and method for treating skin | |
US5962482A (en) | Method of reducing cellulite in mamalian skin | |
EP1667699B1 (en) | Compositions comprising lotus extracts and methyl donors | |
UA81408C2 (en) | Topical pharmaceutical composition and use thereof for the preparation of medicament for treatment of dermatitis and mucosae inflammatory conditions | |
DE69400353T2 (en) | Slimming composition | |
EP1074245A2 (en) | Composition using mineral salts for therapeutic treatment | |
US20140271509A1 (en) | Compositions for Skin Lightening and/or Brightening | |
JP7483331B2 (en) | Compositions and methods for treating skin conditions using light and glucosamine hydrochloride | |
EP0914138B1 (en) | Complex preparations characterised by a betain content | |
CA2132170A1 (en) | Medicine for the treatment of alopecia and skin diseases | |
US9682025B2 (en) | Combination of active agents for oral administration for improving the quality of nails | |
MXPA01000485A (en) | Skin and tissue care and/or treatment agent | |
CN112675094A (en) | Plant extract, repairing composition, skin care product and preparation method thereof | |
KR101186096B1 (en) | Oral compositions for the treatment of cellulite | |
EP4132459A1 (en) | Composition for the making of an emulsifiable triphasic formulation, and kit for the use of such composition | |
CZ2001184A3 (en) | Preparation for skin and tissue care | |
AU711191B2 (en) | Preparations for use in cosmetics and dermatology | |
KR101851559B1 (en) | Compositions for activating NGF and anti-aging cosmetic composition containing the same | |
KR20230060659A (en) | Cosmetic composition for exfoliating and pad having the same | |
KR20010010655A (en) | Composition for growthing hair | |
TWM656940U (en) | Liposome-coated structure with plant-derived bioactive peptides | |
MXPA98010220A (en) | Complex preparations characterized by beta content | |
MXPA00009058A (en) | Method of reducing cellulite in mammalian skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |